IONS

33.65

2.64% 0.865

Dopo l'orario di chiusura: 33.65 0.005 +0.01%

Ionis Pharmaceuticals Inc (IONS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$32.78

Aprire:

$33.22

Volume 24 ore:

2.00M

Relative Volume:

1.16

Capitalizzazione di mercato:

$4.61B

Reddito:

$705.14M

Utile/perdita netta:

$-453.90M

Rapporto P/E:

-11.07

EPS:

-3.04

Flusso di cassa netto:

$-551.29M

1 W Prestazione:

+13.13%

1M Prestazione:

+24.20%

6M Prestazione:

-13.29%

1 anno Prestazione:

-19.84%

Intervallo 1D:

$32.97

$33.98

Intervallo di 1 settimana:

$29.42

$33.98

Portata 52W:

$23.95

$52.34

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Nome

Ionis Pharmaceuticals Inc

Settore

Healthcare (1150)

Industria

Biotechnology (676)

Telefono

(760) 931-9200

Indirizzo

2855 GAZELLE COURT, CARLSBAD, CA

Dipendente

Cinguettio

@ionispharma

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

IONS's Discussions on Twitter

Confronta IONS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
IONS Ionis Pharmaceuticals Inc	33.65	4.61B	705.14M	-453.90M	-551.29M	-3.04
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-07	Iniziato	H.C. Wainwright	Buy
2025-03-31	Iniziato	Redburn Atlantic	Neutral
2024-08-02	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-07-24	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-07-16	Ripresa	Jefferies	Buy
2024-06-14	Aggiornamento	Bernstein	Underperform → Mkt Perform
2024-04-10	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2024-01-02	Aggiornamento	BofA Securities	Neutral → Buy
2023-10-23	Aggiornamento	BofA Securities	Underperform → Neutral
2023-09-29	Iniziato	Raymond James	Strong Buy
2023-07-31	Aggiornamento	Citigroup	Neutral → Buy
2023-06-07	Ripresa	Piper Sandler	Overweight
2023-05-04	Aggiornamento	Citigroup	Sell → Neutral
2023-03-21	Iniziato	Bernstein	Underperform
2022-12-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-09-09	Ripresa	Morgan Stanley	Overweight
2022-07-18	Ripresa	Oppenheimer	Outperform
2022-03-31	Ripresa	Piper Sandler	Overweight
2022-03-01	Iniziato	Citigroup	Sell
2022-03-01	Iniziato	Guggenheim	Buy
2022-02-01	Downgrade	BofA Securities	Buy → Underperform
2021-12-14	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-05-07	Aggiornamento	UBS	Sell → Neutral
2021-03-01	Aggiornamento	Barclays	Underweight → Equal Weight
2020-12-16	Iniziato	UBS	Sell
2020-12-15	Aggiornamento	Cowen	Market Perform → Outperform
2020-09-14	Ripresa	JP Morgan	Neutral
2020-09-02	Iniziato	The Benchmark Company	Hold
2020-06-01	Ripresa	Oppenheimer	Outperform
2020-05-13	Iniziato	RBC Capital Mkts	Outperform
2020-03-05	Iniziato	Citigroup	Buy
2019-12-13	Iniziato	Oppenheimer	Outperform
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-11-07	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2019-09-10	Aggiornamento	Bernstein	Mkt Perform → Outperform
2018-08-08	Reiterato	Stifel	Hold
2018-08-07	Reiterato	Stifel	Hold
2018-05-08	Downgrade	Evercore ISI	Outperform → In-line
2017-10-06	Ripresa	Goldman	Sell
2017-08-17	Iniziato	Evercore ISI	Outperform
2017-08-09	Reiterato	Stifel	Hold
2017-03-10	Downgrade	Goldman	Neutral → Sell
2016-12-28	Reiterato	BMO Capital Markets	Outperform
2016-12-27	Reiterato	Leerink Partners	Mkt Perform

Mostra tutto

Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie

May 05, 2025

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com

May 05, 2025

Spinocerebellar Ataxias Pipeline 2025: Comprehensive - openPR.com

May 05, 2025

Oligonucleotide Delivery System Market Key Players Analysis - openPR.com

May 05, 2025

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts - Yahoo Finance

May 05, 2025

Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway - MSN

May 05, 2025

May 03, 2025

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View - MSN

May 03, 2025

May 02, 2025

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow

May 02, 2025

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 02, 2025

Analysts Just Shipped A Substantial Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Estimates - simplywall.st

May 02, 2025

Earnings call transcript: Ionis Pharmaceuticals beats Q1 2025 forecasts - Investing.com Australia

May 02, 2025

Ionis Pharmaceuticals (IONS) Target Price Increased to $50 After Strong Q1 | IONS Stock News - GuruFocus

May 01, 2025

Ionis Pharmaceuticals Ups Revenue Forecast After Q1 Success - Finimize

May 01, 2025

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says - marketscreener.com

May 01, 2025

IONIS: Guggenheim Maintains Buy Rating but Lowers Price Target | - GuruFocus

May 01, 2025

Ionis Pharmaceuticals (IONS) Receives Price Target Boost from HC Wainwright | IONS Stock News - GuruFocus

May 01, 2025

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025

Ionis Pharmaceuticals (IONS) Target Price Adjusted by Guggenheim | IONS Stock News - GuruFocus

May 01, 2025